- Home
- BOLD vs CRIS Comparison
BOLD vs CRIS Comparison
Compare BOLD & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- CRIS
- Stock Information
- Founded
- BOLD 2018
- CRIS 2000
- Country
- BOLD United States
- CRIS United States
- Employees
- BOLD N/A
- CRIS N/A
- Industry
- BOLD
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BOLD
- CRIS Health Care
- Exchange
- BOLD Nasdaq
- CRIS Nasdaq
- Market Cap
- BOLD 25.5M
- CRIS 22.9M
- IPO Year
- BOLD 2024
- CRIS 2000
- Fundamental
- Price
- BOLD $1.22
- CRIS $1.65
- Analyst Decision
- BOLD Buy
- CRIS Strong Buy
- Analyst Count
- BOLD 4
- CRIS 2
- Target Price
- BOLD $4.00
- CRIS $16.50
- AVG Volume (30 Days)
- BOLD 120.5K
- CRIS 66.6K
- Earning Date
- BOLD 11-06-2025
- CRIS 11-13-2025
- Dividend Yield
- BOLD N/A
- CRIS N/A
- EPS Growth
- BOLD N/A
- CRIS N/A
- EPS
- BOLD N/A
- CRIS N/A
- Revenue
- BOLD N/A
- CRIS $11,405,000.00
- Revenue This Year
- BOLD N/A
- CRIS $2.72
- Revenue Next Year
- BOLD N/A
- CRIS $8.27
- P/E Ratio
- BOLD N/A
- CRIS N/A
- Revenue Growth
- BOLD N/A
- CRIS 12.24
- 52 Week Low
- BOLD $1.00
- CRIS $1.02
- 52 Week High
- BOLD $3.75
- CRIS $5.51
- Technical
- Relative Strength Index (RSI)
- BOLD 63.15
- CRIS 42.93
- Support Level
- BOLD $1.10
- CRIS $1.58
- Resistance Level
- BOLD $1.25
- CRIS $1.74
- Average True Range (ATR)
- BOLD 0.05
- CRIS 0.09
- MACD
- BOLD 0.01
- CRIS -0.00
- Stochastic Oscillator
- BOLD 75.00
- CRIS 17.34
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.